Published in Law and Health Weekly, September 6th, 2008
As a result of the settlement, AMS' '612 patent remains valid and in force and ADESA and LAI may continue to use their technology in the marketplace.
AMS, ADESA and LAI all are satisfied with the resolution of the lawsuits.
AMS' patent infringement case against Manheim and its affiliates still remains pending.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.